r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
EMD Serono
ClinicalTrials.gov Identifier:
NCT01034735
First received: December 16, 2009
Last updated: October 22, 2013
Last verified: October 2013

December 16, 2009
October 22, 2013
July 2008
August 2008   (final data collection date for primary outcome measure)
Primary endpoints were the pharmacokinetic (PK) parameters of r-hGH: the area under the serum concentration-time curve from time zero to last detectable serum concentration (AUC0 t) and the maximum observed serum concentration (Cmax). [ Time Frame: 24 hours post r hGH dose ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01034735 on ClinicalTrials.gov Archive Site
  • Secondary endpoints included further PK parameters. [ Time Frame: 15 +/-3 days post last r hGH dose ] [ Designated as safety issue: No ]
  • Safety and tolerability were evaluated by adverse events (AEs), medical history, physical examination, vital signs, local tolerability, visual analog scale (VAS), ECG recordings, glycemia measurements and laboratory tests. [ Time Frame: 15 +/-3 days post last r hGH dose ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial
Phase I, Open Label, Randomised Three-way Cross Over, Single-centre Trial to Assess the Bioequivalence for Two Concentrations of the New r-hGH Liquid Multidose Formulation Versus the r-hGH Freeze-dried Multidose Formulation Administered in Healthy Volunteers

The primary objective of the trial was to assess the bioequivalence for two concentrations (5.83 mg/mL and 8 mg/mL) of the new r-hGH liquid multidose formulation using the r hGH freeze-dried multidose formulation (Saizen® 8 mg, 8.8 mg/1.51 mL) as reference.

Each volunteer received three r hGH treatments, with each treatment being administered as a single subcutaneous dose of 4 mg r-hGH in a randomized sequence with at least one week of wash-out period between successive treatments.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
  • Growth Failure
  • Growth Hormone Deficiency
  • Biological: r-hGH liquid (Saizen)
    Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
  • Biological: r-hGH liquid (Saizen)
    Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
  • Biological: r-hGH freeze-dried
    Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
  • Experimental: Arm A
    Intervention: Biological: r-hGH liquid (Saizen)
  • Experimental: Arm B
    Intervention: Biological: r-hGH liquid (Saizen)
  • Experimental: Arm C
    Intervention: Biological: r-hGH freeze-dried
Liedert B, Forssmann U, Wolna P, Golob M, Kovar A. Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation. BMC Clin Pharmacol. 2010 Oct 20;10:14.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
Not Provided
August 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

Main inclusion criteria:

  1. Male and female aged 18 to 45 years, inclusive; who are able to read, to write and to fully understand German language
  2. Had given written Informed Consent
  3. Had a body weight greater than 55 kg and a body mass index (BMI) of >20 and < or = 30 kg/m2 (BMI = weight (kg)/height (m)2)
  4. Had vital signs in the following normal range:

    Ear body temperature: 35.0 - 38.0°C

    Blood pressure (BP) - after at least 3 minutes of rest, measured in the supine position:

    systolic blood pressure: 90 - 145 mmHg diastolic blood pressure : 50 - 95 mmHg Pulse rate (PR): after at least 3 minutes of rest, measured in the supine position: 40 90 bpm

  5. Smoked less than 10 cigarettes per day, consented to smoke less than 5 cigarettes per day during the trial period and were able to refrain from smoking during the confinement period
  6. Were able to communicate well with the Investigator and willing to comply with the requirements of the entire trial
  7. Were willing to undergo pituitary down-regulation by intravenous infusion with somatostatin for 25 hours

    If female:

  8. Had a negative serum pregnancy test within three weeks prior to trial start and a negative urine pregnancy test at the day before dosing
  9. Were pre-menopausal and using an adequate method of non-hormonal contraception (2 barrier methods, or one barrier method with spermicide, or non-hormonal intrauterine device), sexual abstinence or females with vasectomised partners during the entire trial

Exclusion Criteria:

Main exclusion criteria:

  1. Any surgical or medical condition, including findings in the medical history or in the pre trial assessments, that in the opinion of the Investigator, constituted a risk or a contraindication for the participation of the subject in the trial or that could have interfered with the trial objectives, conduct or evaluation
  2. Had any clinically significant abnormal laboratory test results in the pre-trial safety laboratory tests or any clinically abnormal findings on the 12 leads resting electrocardiogram (ECG) that in the opinion of the Investigator may have increased the safety risk to the subject
  3. Had positive results for drugs of abuse or alcohol test
  4. Had positive results from serology examination for Hepatitis B surface antigen (HBsAg) (not due to vaccination), Hepatitis B core antibody (HBcAb) (if positive, was to be verified by test for anti-Hbc-IgM), Hepatitis C Virus (anti-HCV) and Human Immunodeficiency Virus (anti-HIV 1 and 2) at screening
  5. History or presence of hypertension or other significant cardiovascular abnormalities
  6. History or presence of cholelithiasis
  7. Significant history or clinical evidence of auto-immune, gastrointestinal, haematological, hematopoietic, hepatic, neurological, pancreatic or renal disease
  8. History or presence of diabetes
  9. History or presence of tumors of the pituitary gland or hypothalamus
  10. Definite or suspected personal history or family history of adverse drug reaction or hypersensitivity to drugs with a similar chemical structure to somatropin or somatostatin or its excipients, use of any chronic medication
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01034735
28798
No
EMD Serono
EMD Serono
Not Provided
Principal Investigator: Michael Lissy, MD AAIPharma Deutschland GmbH & Co. KG
EMD Serono
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP